SCHEMBL16655568

SCHEMBL16655568

C=CCOc1cc2ccn(-c3nn(C4Cc5ccccc5N(C(=O)C=C)C4)c4ncnc(N)c34)c2cc1F

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BTK Q06187 15/20 0.39
EGFR P00533 5/20 0.38
PIK3CD O00329 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16655856 0.97 BTK (0.39) BTKEGFRPIK3CD
SCHEMBL16656077 0.91 BTK (0.44) BTKEGFR
SCHEMBL16655623 0.89 BTK (0.45) BTKEGFRPIK3CD
SCHEMBL16656024 0.88 BTK (0.44) BTKEGFR
SCHEMBL16655540 0.88 BTK (0.45) BTKEGFRPIK3CD
SCHEMBL16655437 0.88 PIK3CD (0.46) BTKPIK3CD
SCHEMBL16655797 0.85 PIK3CD (0.46) BTKPIK3CD
SCHEMBL16655749 0.85 EGFR (0.43) BTKEGFR
SCHEMBL16655572 0.84 PIK3CD (0.47) BTKPIK3CD
SCHEMBL16655543 0.83 RET (0.43) BTKEGFRPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US claimed
EP-3057970-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Medivation Technologies, Inc. (US) 2016-08-24 EP claimed
WO-2015058084-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2015-04-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317140-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB BTK 1/4885EGFR 828/4885PIK3CD 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.